Lifeforce Capital

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

MindRight Health, Inc., founded in 2019 and based in Newark, New Jersey, offers mental health coaching through text messaging to support communities in overcoming trauma. The company aims to enhance health equity by providing accessible and inclusive mental health care, particularly for communities of color and low-income families. MindRight partners with healthcare payers and providers to deliver culturally-responsive coaching, ensuring that members receive support seven days a week throughout the year. By matching users with specific coaches based on their profiles, MindRight creates a continuum of nonclinical support tailored to youth who may avoid traditional clinical services due to stigma and accessibility issues. Additionally, the company supplies partners with real-time data on mental health needs within the community, helping to anticipate and prevent potential mental health crises.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Founded in 2021, Cylinder delivers personalized, clinician-backed care to those suffering from digestive issues through its virtual health platform and has helped nearly 100K members to date. Cylinder's platform offers dynamically updated content and care plans designed to improve engagement and outcomes. Members enjoy access to a dedicated care team nationwide, including health coaches, registered dietitians, and GI doctors. Cylinder’s vision is to create a world where people receive convenient, personalized, and affordable access to the quality digestive health care they need to improve their overall health. Trusted by businesses including Texas A&M University, US Foods, and more, Cylinder showcases up to 5:1 ROI and an average of 13% employee engagement. Learn more at cylinderhealth.com.

Synapticure is a virtual clinical care platform dedicated to supporting patients with neurodegenerative diseases, including dementia, Parkinson's, and ALS, throughout the United States. Founded by patients, the company offers comprehensive care services that include access to disease-specific neurologists, speech and language therapy, and 24/7 care coordination. Utilizing advances in science, technology, and computational analytics, Synapticure ensures that patients receive tailored treatment and support in their own homes. The platform integrates medical, dental, vision, and life insurance plans to facilitate easy access to a range of healthcare services, including behavioral health support such as psychiatry and therapy, all aimed at enhancing the quality of life for individuals facing these challenging conditions.

64x Bio develops a platform aimed at accelerating the discovery and optimization of mammalian cell lines for biomanufacturing and therapeutics. The company employs a high-throughput discovery and screening approach combined with an integrated computational design loop to create genetically engineered cell lines tailored for the production of viral vectors. This focus is particularly relevant for cell and gene therapies, as it enhances the efficiency of viral vector production. By providing purpose-built cell lines, 64x Bio enables pharmaceutical and biotechnology companies to improve their manufacturing capacity and reduce costs, ultimately facilitating the timely delivery of innovative therapies to patients.

PostEra is a company focused on advancing drug discovery through innovative technology and strategic partnerships within the biopharma sector. Founded in 2019 and based in Santa Clara, California, PostEra provides medicinal chemistry services that combine molecular design with chemical synthesis. The company has developed algorithms that predict bioactivity and chemical reaction outcomes more effectively than traditional methods, addressing complex challenges in drug development. PostEra collaborates with major pharmaceutical companies and institutions, having secured significant funding and established multi-year partnerships with organizations such as Amgen, Pfizer, and the NIH. Additionally, the company has played a pivotal role in the COVID Moonshot initiative, which is recognized as the largest open-science drug discovery effort to date. By automating the drug development process through its machine learning platform, PostEra aims to enhance the speed, safety, and cost-effectiveness of bringing new drugs to market.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatments through innovative therapies. The company specializes in the development of antibody-drug conjugates (ADCs), utilizing a unique protein engineering approach that enhances the effectiveness of these targeted therapies. Mythic Therapeutics' technology significantly improves the uptake of therapeutic agents in cancerous cells while minimizing their release in healthy cells, thereby increasing efficacy across various cancer types. This method not only boosts the potency of the treatments but also ensures a favorable safety profile, enabling healthcare providers to harness the full potential of ADCs. As such, Mythic Therapeutics aims to make a meaningful impact on cancer care by addressing a broad spectrum of tumor targets.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Bayesian Health Inc. is a digital health company based in New York, established in 2016. It specializes in an AI-driven platform that enhances patient monitoring by assessing illness severity and detecting changes in acuity. This technology integrates with hospital electronic medical records (EMR), allowing clinical staff and hospital leadership to access real-time data and insights. The platform provides actionable early detection alerts and supports decision-making in complex clinical environments, ultimately optimizing patient care throughout their hospital stay. By leveraging existing investments in EMR systems, Bayesian Health enables healthcare providers to make informed, data-driven decisions that improve safety and efficiency in patient management.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Sempre Health, Inc. operates a behavior-based healthcare pricing platform that collaborates with health plans and pharmaceutical manufacturers to offer dynamic co-payment adjustments based on individual patient adherence and behavior. Founded in 2015 and based in San Francisco, the company analyzes prescription records to forecast the most appropriate price for medications based on a patient's timely adherence. Patients receive personalized SMS messages that inform them of potential discounts and encourage prompt prescription refills, such as alerts indicating that filling a prescription today may cost $10, while delaying could raise the price to $30. This innovative approach not only aims to improve patients' access to affordable care but also generates valuable real-world data on patient price sensitivities and cost behaviors.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the development of small molecule therapeutics targeting protein misfolding diseases. Founded in 2016, the company focuses on conditions such as Alzheimer's and Parkinson's diseases, type 2 diabetes, and various rare forms of amyloidosis. Wren's proprietary technology platform is grounded in a deep understanding of the origins of these diseases, drawing on extensive scientific research conducted at the University of Cambridge and Lund University. Through this innovative platform, Wren aims to advance drug discovery and development for a range of serious neurological and rare disorders.

Sitka, Inc. operates an online communication platform that connects patients with healthcare providers across various specialties, including endocrinology, neurology, orthopedics, pulmonology, and rheumatology. Founded in 2018 by experts in healthcare, technology, and policy, the company aims to transform specialty care in the United States by enhancing the capabilities of primary care providers and facilitating patient involvement in their care. The platform allows for personalized consultations, such as interpreting MRI results with board-certified doctors, thereby improving patients' understanding of their health conditions and enabling better decision-making. Headquartered in Carmel, California, Sitka is supported by a range of investors and is dedicated to fostering effective and trusted care delivery for all patients through its innovative solutions.

People Science is a technology-driven research and development platform focused on alternative medicine. The company facilitates connections between health-conscious individuals, medical professionals, and research scientists while supporting manufacturers in creating products grounded in scientific testing. By providing a scaled research platform, People Science enables customers to identify alternative medicines that may aid in their wellness journeys, ensuring that these solutions are backed by rigorous research and evidence.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care, dermatology, animal health, eye care, and oral care. Based in Woodstock, Georgia, and incorporated in 1999, the company offers over 100 commercially available products worldwide. Its key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for managing dermatoses; Celacyn gel for scar management; and SebuDerm for seborrhea relief. Additionally, Sonoma provides Acuicyn for eye care, Microcyn for expedited wound healing, and various products targeting animal health, such as MicrocynAH and MicrocynVS. The company's focus on addressing unmet medical needs in chronic skin conditions significantly contributes to enhancing patient care while aiming to reduce overall healthcare costs. Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. and rebranded in December 2016.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Notable Labs, Inc. is a clinical-stage company based in Foster City, California, focused on developing personalized testing services for cancer patients, particularly those with brain cancer. The company operates a platform that conducts drug combination experiments on tumors, providing actionable reports to doctors. These reports prioritize combinations of FDA-approved treatments that can be immediately prescribed, avoiding the need for lengthy clinical trials. Notable Labs utilizes its proprietary Predictive Precision Medicines Platform to bio-simulate cancer treatments, predicting patient responses to specific therapies. This approach aims to streamline the identification of patients likely to benefit from targeted treatments, thereby enhancing therapeutic development for cancer care.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the development of small molecule therapeutics targeting protein misfolding diseases. Founded in 2016, the company focuses on conditions such as Alzheimer's and Parkinson's diseases, type 2 diabetes, and various rare forms of amyloidosis. Wren's proprietary technology platform is grounded in a deep understanding of the origins of these diseases, drawing on extensive scientific research conducted at the University of Cambridge and Lund University. Through this innovative platform, Wren aims to advance drug discovery and development for a range of serious neurological and rare disorders.

Cricket Health Inc. is a specialty kidney care provider focused on delivering integrated nephrology and dialysis services for individuals with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Founded in 2015 and based in San Francisco, California, the company employs a technology-enabled, evidence-based approach to manage kidney diseases. Cricket Health aims to enhance patient outcomes and value for healthcare partners by providing multidisciplinary care both in-person and virtually. Their services are designed to keep patients healthy, reduce hospitalizations, accelerate access to transplants, and promote home dialysis adoption. By identifying at-risk patients and acting early, Cricket Health supports personalized treatment options that include transplant support, home dialysis, conservative care, and in-center dialysis.

Sempre Health, Inc. operates a behavior-based healthcare pricing platform that collaborates with health plans and pharmaceutical manufacturers to offer dynamic co-payment adjustments based on individual patient adherence and behavior. Founded in 2015 and based in San Francisco, the company analyzes prescription records to forecast the most appropriate price for medications based on a patient's timely adherence. Patients receive personalized SMS messages that inform them of potential discounts and encourage prompt prescription refills, such as alerts indicating that filling a prescription today may cost $10, while delaying could raise the price to $30. This innovative approach not only aims to improve patients' access to affordable care but also generates valuable real-world data on patient price sensitivities and cost behaviors.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Sitka, Inc. operates an online communication platform that connects patients with healthcare providers across various specialties, including endocrinology, neurology, orthopedics, pulmonology, and rheumatology. Founded in 2018 by experts in healthcare, technology, and policy, the company aims to transform specialty care in the United States by enhancing the capabilities of primary care providers and facilitating patient involvement in their care. The platform allows for personalized consultations, such as interpreting MRI results with board-certified doctors, thereby improving patients' understanding of their health conditions and enabling better decision-making. Headquartered in Carmel, California, Sitka is supported by a range of investors and is dedicated to fostering effective and trusted care delivery for all patients through its innovative solutions.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Floreo Inc. is a developer of a virtual reality learning platform focused on teaching social and communication skills to individuals with autism spectrum disorder, ADHD, and anxiety. Founded in 2016 and based in Washington, D.C., Floreo's application allows supervising adults to monitor and guide users' learning experiences. The platform is utilized by over 100 therapy clinics and school districts, marking Floreo as a pioneer in digital therapeutic reimbursement with an approved CPT 3 reimbursement code. Additionally, the company has partnered with Meta to enhance the accessibility of its virtual reality solutions in public schools, aiming to improve real-world skills for those with developmental challenges.

Notable Labs, Inc. is a clinical-stage company based in Foster City, California, focused on developing personalized testing services for cancer patients, particularly those with brain cancer. The company operates a platform that conducts drug combination experiments on tumors, providing actionable reports to doctors. These reports prioritize combinations of FDA-approved treatments that can be immediately prescribed, avoiding the need for lengthy clinical trials. Notable Labs utilizes its proprietary Predictive Precision Medicines Platform to bio-simulate cancer treatments, predicting patient responses to specific therapies. This approach aims to streamline the identification of patients likely to benefit from targeted treatments, thereby enhancing therapeutic development for cancer care.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Clover Health Inc. is a health insurance provider focused on offering Medicare Advantage plans to senior citizens, primarily based in New Jersey. Founded in 2014 and headquartered in San Francisco, the company also operates in several other states, including Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health employs a Preferred Provider Organization (PPO) platform designed to enhance the quality of care for its members and their physicians. Utilizing patient-centered analytics and a dedicated care management team, Clover aims to identify potential health risks and deliver preventive care, which helps in reducing avoidable healthcare expenditures and managing chronic diseases. The company’s proprietary software platform, Clover Assistant, equips physicians with personalized insights for early detection and management of chronic conditions. Clover Health operates mainly through its Insurance segment, which includes its PPO and Health Maintenance Organization (HMO) plans, while also participating in the ACO REACH Model in its Non-Insurance segment.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Advantia Health is dedicated to helping women manage their health and the health of their families. Advantia Health is an integrated healthcare delivery company that helps women manage their health and the health of their families. The company provides high quality, high-value care using technology, and highly efficient outpatient facilities. It was founded in 2014 and is headquartered in Arlington, Virginia.

dr.consulta is a healthcare company based in Brazil that operates a network of clinics focused on providing affordable medical care to uninsured individuals. Initially established as a full stack primary care provider, it has since evolved into a Health Maintenance Organization (HMO). The company offers a range of outpatient services, including scheduled appointments, consultations, and examinations for various medical issues, such as gynecology and pediatrics. By enabling users to book appointments with healthcare professionals, dr.consulta aims to enhance access to quality healthcare services at a lower cost.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Included Health is a healthcare company that offers a blend of virtual care, navigation, and community-based services aimed at enhancing the overall healthcare experience. By integrating technology with personalized care, the company provides members with guidance and advocacy for a wide range of health needs, including urgent and primary care, behavioral health, and specialty services. Included Health focuses on ensuring that individuals receive the appropriate care at the right time, utilizing compassionate and data-driven approaches to improve clinical outcomes and member satisfaction. Through its innovative model, Included Health seeks to redefine healthcare accessibility and quality for all individuals.

Aspire Health is a new healthcare company that specializes in providing an extra layer of support to patients facing a serious illness. The company's clinicians are experts in providing patients with relief from the symptoms, pain, and stress of a serious illness, helping patients and caregivers navigate the healthcare system; guiding patients and caregivers through difficult and complex treatment choices, and providing emotional and spiritual support to patients and their families. The company's practice in each market provides disease management and care coordination across many settings including outpatient clinics, patients’ homes, and assisted living centers. It was established in 2012 and is based in Nashville, Tennessee, United States.

Amazon One Medical is a members-only technology platform offering an array of concierge medical services. The integration of these elements allows a seamless experience that not only saves the patients time and money but also leads to better health outcomes and happier lives. The company attracts the highest caliber team of healthcare providers, allowing them to practice medicine the way it should be. It makes access to care frictionless with face-to-face virtual video visits available anytime. It allows practicing medicine the way it should be practiced, focusing on improving the patient experience and challenging the healthcare status quo.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.